The paper by Stevinson and co-workers (February 2003 JRSM 1 ) suggests that people undergoing carpal tunnel surgery are not helped by homeopathic arnica. The authors themselves describe the study as preliminary, and it has several important methodological flaws. To begin with, they failed to carry out a power calculation before conducting the research. They suggest that there were no reliable data on which to base a formal sample size calculation. However, they could have used the data from this pilot study to calculate a post-hoc power analysis in order to establish the robustness of their conclusions and determine the appropriate sample size for a full study.
Secondly, poor adherence to the treatment and the fact that the data were not normally distributed (the actual distributions are not presented in the paper) make it difficult to determine whether their results are influenced by outliers. Furthermore, Stevinson et al. do not report how outliers were dealt with, which is particularly relevant in small studies.
The researchers claim that the 'randomization procedure resulted in similar patient characteristics in each group for most variables', but they did not compare patient characteristics using statistical apalysis. In their Table 1 the preoperative pain for the arnica 6C group is reported as 3, with a range of 0-70. If this is not an error, then the patients in the arnica 6C group appear to be very different from the other two groups. The researchers also say that there were more male patients in the arnica 6C group. This suggests that there are systematic differences between the groups on characteristics that may have affected the outcome.
Furthermore, although the researchers report that oral analgesic medication (paracetamol or diclofenac) was prescribed, the actual use of these agents is not adequately presented in the study. Table 5 gives the numbers of tablets taken, but paracetamol and diclofenac (different types of analgesic) are grouped together, rather than presented separately, and details of dosages are not provided. This is a serious omission.
There is no doubt that rigorous studies are required to assess the usefulness and effectiveness of homeopathy. Unfortunately, rather than provide any clear evidence for or against the use of arnica postoperatively in carpal tunnel surgery, this article will simply be added to the list of homeopathic studies that raise questions about methodological rigour and practical relevance. 1 is open to criticism. The number of participants was small and it is doubtful if they took the medicine correctly. Although arnica 30C had no appreciable effect, the patients taking arnica 6C needed fewer painkillers-indicating, I would have thought, that arnica 6C was effective. The operation for carpal tunnel syndrome, if well done, results in very little swelling or bruising. Arnica is particularly efficacious where there is bruising and swelling. I used it for more than 30 years in my National Health Service practice for mothers after childbirth, and they would certainly testify to its effectiveness. Finally, in the Discussion section of the paper, the authors say that the trial did not rule out the possibility that individual patients could benefit from arnica. It would be a tragedy if this effective, non-toxic and inexpensive medicine was denied patients because scientists cannot believe that it works. In homeopathic proving studies, remedies are usually given to healthy individuals in 30C potency, twice a day, for one to two weeks. This usually triggers symptoms in susceptible individuals who 'prove'. These symptoms are then recorded by the homeopath and historically have formed the basis of the homeopathic materia medicas. When a patient is unwell, 'the remedy picture' described in the materia medica is then matched to the patient's symptoms and the most appropriate remedy selected, hence the term 'like cures like'. Stevinson et al. 1 gave a potency and posology of arnica that, according to basic homeopathic principles, would be very likely to trigger a proving reaction either during or a few days after the operation. I am not aware that any of the individuals involved in the study was a practising homeopath so this may well be an oversight. It does, however, make the study very difficult to interpret; is it a proving study of arnica, in which case one would have expected the groups undergoing treatment to be worse than the controls, or is it a therapeutic study of arnica, in which case why would the investigators choose a 'proving dose'? This might represent a fundamental methodological flaw which could throw some doubt on the study's conclusions. Of course, the principles of homeopathic practice are unproven, but until we know whether they are correct or incorrect, we should certainly take note of them in studies designed to evaluate the effects of homeopathy. Stevinson and her co-workers 1 deal briefly with the issue of statistical power, stating that the lack of evidence from previous studies prevented them from carrying out a formal power calculation. They then argue that, since statistically significant effects have previously been observed in groups of 11-30 patients, a trial size of around 60, divided over three arms, should suffice for a preliminary study. What they signally fail to do is to follow the implications of their choice. A straightforward power calculation shows that so small a trial would have only a 1 in 4 chance of confirming the efficacy of such well-established conventional postoperative treatments as the use of tramadol for pain relief and ondansetron for nausea. Had the authors performed such a 'reality check', it would have put their negative finding in its proper context. Furthermore-and contrary to the impression given by the authors-estimates of suitable trial sizes can be obtained even in the absence of prior insight into likely effect sizes. This is made possible by considering what constitutes a 'worthwhile' effect. A therapy that outperforms placebo in a high proportion of patients is clearly more worthwhile than one that does not. In quantitative terms, a worthwhile therapy is thus one requiring a relatively low 'number needed to treat' (NNT)-i.e. the number of patients who need to receive the therapy in order for it to benefit one patient. In the case of pain relief, for example, therapies with NNTs as high as 5 are still considered effective.
Taking an NNT of 5 to be a reasonable upper limit in the case of arnica leads directly to an estimate of appropriate trial size. Using standard statistical power theory, one can show that a randomized placebo-controlled trial needs around 100 patients per arm-i.e. a total of around 200 patients-in order to detect a clinically worthwhile effect with the standard 80% power. Smaller trials-all too common in complementary medicine-face a substantial risk of failing to detect worthwhile effects. One can show that a '50-50' rule applies, in which placebocontrolled trials with fewer than 50 patients per arm face a greater than 50% chance of failing to detect a worthwhile effect. This is not to say that small studies are worthless; when combined in a meta-analysis, they can provide useful insights. The fact remains, however, that the size of individual trials capable of detecting worthwhile effects is considerably larger than many seem to believe.
Certainly, if trials as small as those typically adopted in studies of complementary therapies had been used to assess the value of well-established conventional therapies, the shelves of hospital pharmacies would look decidedly bare.
The trial by Stevinson et al. 1 was designed as a preliminary investigation but was analysed and reported as if it were a definitive trial.
The placebo group required 45% more postoperative analgesia than one of the verum groups (arnica 6C), a result which, if confirmed, is certainly clinically relevant. This verum group also had lower pain scores and, of course, these two variables are inversely related (i.e. for the same underlying pain level, patients taking more analgesia will report lower pain scores than those taking less). Analysing these variables separately therefore underestimates the effect size-in this case, the pain-reducing effect of arnica 6C. This goes unremarked in the paper.
The CONSORT statement on the reporting of randomized trials calls for reporting of estimates of precision (95% confidence intervals), stating that 'They are especially valuable in relation to non-significant differences, for which they often indicate that the result does not rule out an important clinical difference'. 2 Regrettably, Stevinson et al. do not report confidence intervals, and their trial came nowhere close to detecting statistical significance for the clinically very significant lower analgesia requirements in one of the active treatment groups.
In a preliminary investigation absence of proof should not be misinterpreted as proof of absence. By analysing the study as a definitive trial, the authors drew conclusions that it was not capable of delivering. Viewed as a feasibility study, it suggests that arnica 6C may be associated with useful benefits in terms of postoperative pain, a conclusion that accords with another published study. 3 It could inform a larger study, including a sample size calculation, outcome measures and their timing. 
